Gastrointestinal (Noncolorectal) Cancer:

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, J. Raoul, S. Zeuzem, M. Poulin-Costello, M. Moscovici, D. Voliotis, J. Bruix for the SHARP Investigators Study Group

Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1. [Abstract]  

P. A. Philip, J. Benedetti, C. Fenoglio-Preiser, M. Zalupski, H. Lenz, E. O'Reilly, R. Wong, J. Atkins, J. Abruzzese, and C. Blanke

Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study
J Clin Oncol (Meeting Abstracts) 2007 25: LBA4509. [Abstract]  

V. Boige, J. Pignon, B. Saint-Aubert, P. Lasser, T. Conroy, O. Bouché, P. Segol, L. Bedenne, P. Rougier, and M. Ychou

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4510. [Abstract]  

M. Stahl, M. K. Walz, M. Stuschke, N. Lehmann, M. H. Seegenschmiedt, J. Riera Knorrenschild, P. Langer, M. Bieker, A. Königsrainer, W. Budach, and H. Wilke

Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTX) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4511. [Abstract]  

P. G. Thirion, S. Michiels, A. Le Maître, J. Tierney on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group

Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4512. [Abstract]  

N. Boku, S. Yamamoto, K. Shirao, T. Doi, A. Sawaki, W. Koizumi, H. Saito, K. Yamaguchi, A. Kimura, A. Ohtsu Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group

Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA4513. [Abstract]  

H. Narahara, W. Koizumi, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, and TS-1 Advanced Gastric Cancer (AGC) Clinical TrialGroup

Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4514. [Abstract]  

V. Heinemann, A. Hinke, S. Böck, R. Labianca, and C. Louvet

Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta- analysis of sixteen randomized trials
J Clin Oncol (Meeting Abstracts) 2007 25: 4515. [Abstract]  

M. Ychou, F. Desseigne, R. Guimbaud, M. Ducreux, O. Bouché, Y. Bécouarn, A. Adenis, C. Montoto-Grillot, E. Luporsi, and T. Conroy

Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4516. [Abstract]  

H. Riess, U. Pelzer, J. Stieler, I. Schwaner, G. Heil, M. Görner, M. Mölle, A. Hilbig, B. Dörken, and H. Oettle

A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003
J Clin Oncol (Meeting Abstracts) 2007 25: 4517. [Abstract]  

M. Posner, K. J. Chang, A. Rosemurgy, J. Stephenson, M. Khan, T. Reid, W. E. Fisher, I. Waxman, D. Von Hoff, and R. Hecht, Jr.

Multi-center phase II/III randomized controlled clinical trial using TNFerade combined with chemoradiation in patients with locally advanced pancreatic cancer (LAPC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4518. [Abstract]  

B. A. Burtness, M. Powell, J. Berlin, D. Liles, A. Chapman, E. Mitchell, A. B. Benson, and Eastern Cooperative Oncology Group

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology
J Clin Oncol (Meeting Abstracts) 2007 25: 4519. [Abstract]  

F. Mornex, T. André, C. Louvet, J. Seitz, M. Ychou, G. Lledo, E. Touboul, C. Partensky, and J. Balosso

Postoperative adjuvant gemcitabine plus oxaliplatin (GemOx) chemotherapy followed by chemoradiation in patients with pancreatic carcinoma: A multicenter phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4520. [Abstract]  

M. J. Moore, G. da Cunha Santos, S. Kamel-Reid, K. Chin, D. Tu, W. Parulekar, O. Ludkovski, J. Squire, F. Richardson, and M. Tsao

The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3
J Clin Oncol (Meeting Abstracts) 2007 25: 4521. [Abstract]  

A. C. Berger, K. Winter, J. Hoffman, W. Regine, R. Abrams, H. Safran, A. Konski, A. Benson, III, J. MacDonald, and C. Willet

Post-resection CA 19–9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704
J Clin Oncol (Meeting Abstracts) 2007 25: 4522. [Abstract]  

R. A. Abrams, K. A. Winter, W. F. Regine, H. Safran, J. P. Hoffman, A. A. Konski, A. B. Benson, J. S. Macdonald, T. A. Rich, and C. G. Willett

Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S)
J Clin Oncol (Meeting Abstracts) 2007 25: 4523. [Abstract]  

D. Schrag, L. Archer, X. Wang, D. Romanus, M. Mulcahy, R. Goldberg, H. Kindler for the Cancer and Leukemia Group B (CALGB)

A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303
J Clin Oncol (Meeting Abstracts) 2007 25: 4524. [Abstract]  

K. Chin, H. Iishi, H. Imamura, O. Kobayashi, H. Imamoto, T. Esaki, M. Kato, Y. Tanaka, and H. Furukawa

Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002)
J Clin Oncol (Meeting Abstracts) 2007 25: 4525. [Abstract]  

F. Lordick, S. Lorenzen, S. Hegewisch-Becker, G. Folprecht, E. Wöll, T. Decker, E. Endlicher, N. Röthling, F. Fend, and C. Peschel

Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1^st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group
J Clin Oncol (Meeting Abstracts) 2007 25: 4526. [Abstract]  

M. Hejna, J. Zacherl, A. Ba-Ssalamah, A. Püspök, U. Pluschnig, T. Brodowicz, C. C. Zielinski, and M. Raderer

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001
J Clin Oncol (Meeting Abstracts) 2007 25: 4527. [Abstract]  

N. Tebbutt, T. Sourjina, A. Strickland, G. Van Hazel, V. Ganju, D. Gibbs, V. Gebski, S. Munro, and M. Cummins

ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4528. [Abstract]  

K. Minashi, A. Ohtsu, K. Mera, M. Muto, T. Yano, M. Tahara, T. Doi, M. Nishimura, and K. Nihei

Combination of endoscopic mucosal resection and chemoradiotherapy as a nonsurgical treatments for patients with clinical stage I esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4529. [Abstract]  

H. Carstens, M. Albertsson, S. Friesland, G. Adell, G. Frykholm, G. Wagenius, H. E. Myrvold, I. Farago, and D. Stockeld

A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4530. [Abstract]  

G. Crehange, F. Bonnetain, S. Seng, T. N'guyen, X. Mirabel, C. Marchal, P. Verrelle, B. Roullet, P. Maingnon, and L. Bedenne

Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT+S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)
J Clin Oncol (Meeting Abstracts) 2007 25: 4531. [Abstract]  

T. Conroy, Y. Yataghene, P. L. Etienne, P. Michel, H. Senellart, J. L. Raoul, L. Mineur, M. Rives, X. Mirabel, and A. Adenis

Definitive chemo-radiotherapy (CRT) with folfox 4 or 5FU-cisplatin as first line treatment for patients (pts) with inoperable esophageal cancer (IEC): Final results of a randomized phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4532. [Abstract]  

L. Kleinberg, M. E. Powell, A. Forastiere, S. Keller, P. Anne, and A. B. Benson

E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus
J Clin Oncol (Meeting Abstracts) 2007 25: 4533. [Abstract]  

B. E. Chatterton, I. Ho-Shon, N. Lenzo, A. Patrikeos, B. Kelley, A. Baldey, J. Ramshaw, and A. Scott

Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
J Clin Oncol (Meeting Abstracts) 2007 25: 4534. [Abstract]  

D. Kandioler, M. Hejna, R. Zwrtek, S. Kappel, C. Bichler, F. Wrba, A. Ba-Ssalamah, C. Zielinski, R. Jakesz, J. Zacherl, and p53 Research Group Study

p53 adapted neoadjuvant therapy for esophageal cancer: Pilot study
J Clin Oncol (Meeting Abstracts) 2007 25: 4535. [Abstract]  

D. Vallboehmer, E. Kuhn, J. Brabender, R. Metzger, U. Warnecke-Eberz, S. E. Baldus, U. Drebber, A. H. Hölscher, and P. M. Schneider

Survivin expression in esophageal cancer: Association with histomorphological response to neoadjuvant therapy and prognosis
J Clin Oncol (Meeting Abstracts) 2007 25: 4536. [Abstract]  

H. H. Helgason, J. Y. Engwegen, A. Cats, H. Boot, M. Kuiper, M. Zapatka, M. Joerger, J. H. Beijnen, and J. H. Schellens

Serum proteomic profiling of advanced gastric cancer and identification of proteomic changes following response to epirubicin, cisplatin and capecitabine chemotherapy as diagnostic and predictive biomarkers
J Clin Oncol (Meeting Abstracts) 2007 25: 4537. [Abstract]  

M. Teo, H. T. Huynh, S. W. Hee, Y. P. Phoon, R. Quek, P. Wang, and H. C. Toh

FOXO3a predicts for survival and its phosphorylated form is downregulated following mTOR or MEK inhibitor therapy in Hepatocellular Carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4538. [Abstract]  

J. Matsubara, Y. Yamada, Y. Hirashima, D. Takahari, N. Tsuda, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, and T. Shimoda

Impact of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), and HER2 expressions on outcomes of patients with gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4539. [Abstract]  

I. Altomare, A. Pennathur, L. Xi, W. E. Gooding, V. R. Litle, J. D. Luketich, and T. E. Godfrey

Molecular detection of occult nodal metastases in esophageal adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4540. [Abstract]  

H. Ishii, J. Furuse, K. Nakachi, E. Suzuki, S. Shimizu, M. Yoshino, M. Satake, and T. Hayashi

Predictive factors of transcatheter arterial chemoembolization for hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4541. [Abstract]  

H. Yoshitomi, A. Togawa, F. Kimura, H. Shimizu, H. Yoshidome, M. Miyazaki, and Chiba study group of adjuvant chemotherapy for pancreatic cancer (CSAP)

A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4542. [Abstract]  

T. Buanes, S. Bernhardt, K. Lislerud, I. Gladhaug, M. Moeller, J. A. Eriksen, and G. Gaudernack

RAS peptide vaccination in resected pancreatic cancer patients - persistence of anti tumour response and long term survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4543. [Abstract]  

S. Cascinu, R. Berardi, S. Siena, R. Labianca, A. Falcone, E. Aitini, S. Barni, F. Di Costanzo, L. Frontini, G. Tonini, and A. Zaniboni

The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD
J Clin Oncol (Meeting Abstracts) 2007 25: 4544. [Abstract]  

S. Al-Batran, J. T. Hartmann, R. Hofheinz, R. Mahlberg, N. Homann, S. Probst, J. Stoehlmacher, M. Fritz, V. Rethwisch, G. Seipelt, and E. Jäger

Modified FOLFOX in combination with docetaxel for patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction: A multicenter phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
J Clin Oncol (Meeting Abstracts) 2007 25: 4545. [Abstract]  

Y. Kang, J. Lee, Y. Min, K. Lee, D. Zang, B. Ryoo, J. Kim, S. Park, W. Kang, and D. Shin

A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4546. [Abstract]  

W. B. Al-Refaie, P. W. Pisters, and G. J. Chang

Gastric adenocarcinoma in young patients: A population-based appraisal
J Clin Oncol (Meeting Abstracts) 2007 25: 4547. [Abstract]  

A. H. Ko, E. Dito, B. Schillinger, A. P. Venook, E. K. Bergsland, D. Wong, J. Allen, and M. A. Tempero

A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual
J Clin Oncol (Meeting Abstracts) 2007 25: 4548. [Abstract]  

T. Evans, R. K. Ramanathan, S. Yazji, R. Glynne-Jones, A. Anthoney, J. Berlin, and J. W. Valle

Final results from cohort 1 of a phase II study of volociximab, an anti-5ß1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4549. [Abstract]  

H. Ueno, T. Okusaka, J. Furuse, K. Yamao, A. Funakoshi, N. Boku, S. Ohkawa, A. Makimoto, and T. Sato

A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4550. [Abstract]  

J. Spano, C. Chodkiewicz, J. Maurel, R. P. Wong, H. S. Wasan, Y. K. Pithavala, P. W. Bycott, K. Liau, S. Kim, and O. Rixe

A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component
J Clin Oncol (Meeting Abstracts) 2007 25: 4551. [Abstract]  

H. Takeuchi, Y. Kitagawa, Y. Saikawa, A. Suto, M. Mukai, T. Nakahara, A. Kubo, and M. Kitajima

Sentinel node mapping for esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4552. [Abstract]  

G. P. Kim, A. L. Oberg, N. R. Foster, A. Jaslowski, P. J. Flynn, D. Campbell, E. Hedrick, L. Gray, A. Grothey, and S. Alberts

Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4553. [Abstract]  

E. Oki, Y. Kakeji, E. Tokunaga, R. Yoshida, A. Egashira, N. Sadanaga, M. Morita, K. Taguchi, M. Kuwano, and Y. Maehara

Akt-mediated YB-1 phosphorylation induces resistance for chemotherapy of gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4554. [Abstract]  

A. D. Wagner, W. Grothe, J. Haerting, G. Kleber, A. Grothey, and W. E. Fleig

Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 4555. [Abstract]  

I. A. Astsaturov, N. J. Meropol, R. K. Alpaugh, J. D. Cheng, N. L. Lewis, M. Beard, A. Rogatko, Z. Xu, L. M. Weiner, and S. J. Cohen

A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4556. [Abstract]  

A. van der Horst-Schrivers, E. de Vries, P. Willemse, I. Kema, T. Links, H. Boezen, and A. Wymenga

Polymorphisms of the serotonin transporter and Monoamine Oxidase A gene in patients with metastatic midgut carcinoid tumors
J Clin Oncol (Meeting Abstracts) 2007 25: 4557. [Abstract]  

L. Kvols, J. E. Glusman, E. A. Hahn, E. Wang, K. Öberg, L. Anthony, T. M. O’Dorisio, W. de Herder, C. H. Darby, B. Wiedenmann, G. and the Pasireotide Carcinoid Study Group

The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR
J Clin Oncol (Meeting Abstracts) 2007 25: 4558. [Abstract]  

E. de Winton, A. Heriot, M. Ng, R. Hicks, A. Hogg, A. Milner, T. Leong, M. Fay, J. MacKay, and S. Ngan

Utility of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging, radiotherapy planning and prognostication of anal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4559. [Abstract]  

B. R. Tan, W. S. Brenner, J. Picus, R. Suresh, S. Sorcher, J. S. James, C. Fournier, and H. L. Mcleod

Biweekly oxaliplatin with gemcitabine and capecitabine in advanced gastrointestinal malignancies: A phase I study
J Clin Oncol (Meeting Abstracts) 2007 25: 4560. [Abstract]  

S. Lorenzen, N. Weigert, V. Heinemann, M. Hentrich, T. Schuster, T. Seroneit, N. Röthling, C. Peschel, and F. Lordick

Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4561. [Abstract]  

T. Ruhstaller, L. Widmer, S. Balmer Majno, W. Mingrone, V. Hess, R. von Moos, M. Borner, A. Schnider, D. Koeberle, and R. Popescu

Preoperative induction chemotherapy with docetaxel-cisplatin followed by concurrent docetaxel-cisplatin and radiation therapy in patients with locally advanced esophageal cancer: A prospective, multicenter phase ll trial of the Swiss Group for Clinical Cancer Research
J Clin Oncol (Meeting Abstracts) 2007 25: 4562. [Abstract]  

D. S. Oh, J. Cooc, S. R. DeMeester, R. Mori, H. Kuramochi, C. Rizzetto, K. Danenberg, P. Danenberg, J. A. Hagen, D. H. Harpole, and T. R. DeMeester

Molecular signature of esophageal adenocarcinoma derived from microarray analysis of paraffin-embedded specimens predicts systemic recurrence following resection
J Clin Oncol (Meeting Abstracts) 2007 25: 4563. [Abstract]  

D. Gold, H. Karacay, C. Chang, E. Rossi, W. McBride, D. Goldenberg, and R. Sharkey

A novel bispecific antibody (bsMAb) construct for nuclear imaging of pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4564. [Abstract]  

D. Zupanc, A. Roth, K. Kolaric, and Z. Tometic

A randomized clinical study of chemoradiotherapy versus radiotherapy in locoregional advanced unresectable esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4565. [Abstract]  

T. Kajiwara, T. Nishina, I. Hyodo, T. Moriwaki, S. Endo, J. Nasu, S. Hori, H. Iguchi, Y. Hiasa, and M. Onji

Impact of gene expression of orotate phosphoribosyl transferase for complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus
J Clin Oncol (Meeting Abstracts) 2007 25: 4566. [Abstract]  

M. B. Thomas, R. Chadha, M. Iwasaki, K. Glover, and J. L. Abbruzzese

The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4567. [Abstract]  

W. M. Eisterer, A. De Vries, B. Spechtenhauser, D. Kendler, A. Königsrainer, H. Nehoda, P. Lukas, E. Wöll, and D. Öfner

Triple induction chemotherapy and chemoradiotherapy in locally advanced esophageal cancer: Final results of a multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4568. [Abstract]  

G. A. Moviglia, C. Gaeta, G. Varela, N. Iraola, A. Paes de Lima, H. Costanzo, P. Farina, F. Bastos, C. Ayala, and G. Schuster

Tumor-associated stroma cell therapy in patients with pancreatic cancer potentiates therapeutic effect of tumor B-cell hybrid (TBH) auto-vaccines
J Clin Oncol (Meeting Abstracts) 2007 25: 4569. [Abstract]  

D. Malka, C. Dromain, F. Farace, S. Horn, J. Pignon, M. Ducreux, and V. Boige

Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring
J Clin Oncol (Meeting Abstracts) 2007 25: 4570. [Abstract]  

J. Ocvirk, M. Rebersek, and E. Skof

Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4571. [Abstract]  

K. Ott, F. Lordick, M. Feith, H. Bartels, U. Fink, H. J. Stein, M. Molls, E. Biemer, and J. Siewert

Cervical squamous cell carcinoma of the esophagus-a unique series of limited resection and free jejunal graft interposition after neoadjuvant RCTx in 94 patients
J Clin Oncol (Meeting Abstracts) 2007 25: 4572. [Abstract]  

R. Krempien, M. W. Munter, C. Timke, H. Friess, G. Hartung, K. K. Herfarth, A. Abdollahi, M. W. Buchler, P. E. Huber, and J. Debus

Cetuximab in combination with intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer: A prospective phase II trial [PARC-Study ISRCTN56652283]
J Clin Oncol (Meeting Abstracts) 2007 25: 4573. [Abstract]  

W. Sun, D. G. Haller, K. Mykulowycz, M. Rosen, M. Soulen, M. Capparo, T. Faust, B. Giantonia, and K. Olthoff

Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4574. [Abstract]  

M. Milella, E. Bria, P. Carlini, F. Cuppone, A. Gelibter, C. Nisticò, E. M. Ruggeri, E. Terzoli, F. Cognetti, and D. Giannarelli

Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations
J Clin Oncol (Meeting Abstracts) 2007 25: 4575. [Abstract]  

L. H. Schwartz, S. Curran, R. Trocola, J. Randazzo, D. Ilson, D. Kelsen, and M. Shah

Volumetric 3D CT analysis - an early predictor of response to therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4576. [Abstract]  

J. Raoul, A. Devillers, A. de Lajarthe, M. Cuggia, E. Boucher, and E. Garin

18-FDG-PET and somatostatin receptor scintigraphy (SRS) can predict disease progression and survival in patients with metastatic endocrine tumors: Results of a prospective study
J Clin Oncol (Meeting Abstracts) 2007 25: 4577. [Abstract]  

R. R. McWilliams, N. R. Foster, F. J. Quevedo, R. F. Marschke, J. W. Kugler, E. L. Friedman, A. J. Jaslowski, J. R. Sande, and S. R. Alberts

NCCTG phase I/II trial (N9943) of gemcitabine and pemetrexed in patients with biliary tract or gallbladder carcinoma: Phase II results
J Clin Oncol (Meeting Abstracts) 2007 25: 4578. [Abstract]  

C. Bauer, M. Dauer, S. Saraj, M. Schnurr, K. Jauch, D. Rüttinger, C. Bruns, B. Emmerich, S. Endres, and A. Eigler

Immunological and clinical response after vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: Results of a phase II-study
J Clin Oncol (Meeting Abstracts) 2007 25: 4579. [Abstract]  

D. Shin, S. Lee, S. Park, J. Park, E. Cho, J. Lee, and W. Lee

Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4580. [Abstract]  

H. A. Gonzalez, Sr., H. Londoño, J. Quiroz, A. Parra, A. Ramirez, M. González, A. Rodríguez, C. Varón, and N. Romero

Chemoimmunotherapy with 5-fluouracil, leucovorin and interferon alpha-2b as adjuvant therapy after surgery in Gastric Carcinoma patients
J Clin Oncol (Meeting Abstracts) 2007 25: 4581. [Abstract]  

M. Aglietta, Y. Pignochino, G. Cavalloni, I. Sarotto, J. Penachioni, C. Zanon, G. Migliardi, W. Piacibello, M. Risio, A. Bardelli, and F. Leone

Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4582. [Abstract]  

A. Maraveyas, M. Holmes, F. Lofts, K. K. Garadi, E. Gardiner, and J. Sgouros

Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4583. [Abstract]  

T. R. Halfdanarson, K. Rabe, J. Rubin, and G. M. Petersen

Pancreatic endocrine tumors (PETs): Incidence and recent trend toward improved survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4584. [Abstract]  

D. Pastorelli, G. Cartei, F. Zustovich, S. Zovato, G. Artioli, R. Ceravolo, M. Nicoletto, S. Binato, and M. Mattiazzi

A phase II study of pegylated liposomial doxorubicin (PLD) and gemcitabine (G) in the treatment of hepatocellular carcinoma (HCC) not suitable for loco-regional therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4585. [Abstract]  

J. M. Brell, K. Matin, T. Evans, R. L. Volkin, G. J. Keifer, J. J. Schlesselman, S. Dranko, L. Rath, A. Schmotzer, and R. K. Ramanathan

Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy. Final results
J Clin Oncol (Meeting Abstracts) 2007 25: 4586. [Abstract]  

K. Ribi, E. Nitzsche, J. Schuller, B. Klaeser, T. Hany, A. Roth, V. Hess, M. Zuend, N. Lombriser, and T. Ruhstaller

PET scanning and patient reported dysphagia before and after chemotherapy (CT) for prediction of pathological response after CT and chemoradiotherapy (CRT) in patients with locally advanced esophageal cancer (EC): A multicenter phase ll trial of the Swiss
J Clin Oncol (Meeting Abstracts) 2007 25: 4587. [Abstract]  

S. Tsujitani, H. Saito, S. Tatebe, and M. Ikeguchi

Tumor progression and chemoradiosensitivity in relation to the expression of apoptosis related proteins in esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4588. [Abstract]  

S. Collette, F. Bonnetain, X. Paoletti, M. Doffoel, O. Bouche, J. L. Raoul, P. Rougier, F. Masskouri, L. Bedenne, and J. C. Barbare

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials
J Clin Oncol (Meeting Abstracts) 2007 25: 4589. [Abstract]  

L. A. Dawson, R. Tse, J. Kim, R. Dinniwell, G. Lockwood, M. Sherman, J. J. Knox, and S. Gallinger

Phase I study of stereotactic radiotherapy for unresectable hepatobiliary cancer and liver metastases
J Clin Oncol (Meeting Abstracts) 2007 25: 4590. [Abstract]  

B. L. Brücher, F. Pühringer-Oppermann, and M. Sarbia

Smad4 is predictive for response in neoadjuvant treated esophageal squamous cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4591. [Abstract]  

T. Andre, P. Afchain, G. Lledo, S. Nguyen, J. Paitel, L. Mineur, P. Artru, F. Selle, A. de Gramont, and C. Louvet

First-line simplified GEMOX (D1-D1) versus classical GEMOX (D1-D2) in metastatic pancreatic adenocarcinoma (MPA). A GERCOR randomized phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4592. [Abstract]  

I. Takeyoshi, F. Makita, Y. Tanahashi, S. Iwazaki, S. Nakamura, H. Ishikawa, T. Ogawa, T. Ohya, S. Kawate, J. Horiguchi, and Y. Morishita

A phase II study of weekly paclitaxel and doxifluridine (an intermediate metabolite of capecitabine) combination chemotherapy for advanced/recurrent gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4593. [Abstract]  

S. Louafi, M. Hebbar, O. Rosmorduc, C. Tesmoingt, A. Asnacios, O. Romano, L. Fartoux, P. Artru, T. Poynard, and J. Taieb

Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO
J Clin Oncol (Meeting Abstracts) 2007 25: 4594. [Abstract]  

A. A. Meluch, D. R. Spigel, F. A. Greco, D. A. Yardley, H. A. Burris, III, C. Farley, J. D. Peyton, D. L. Shipley, R. G. Steis, and J. D. Hainsworth

Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4595. [Abstract]  

A. H. Ko, J. Scott, M. A. Tempero, and J. W. Park

Detection and significance of circulating tumor cells (CTC) in patients with metastatic pancreatic cancer (PC) receiving systemic therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4596. [Abstract]  

S. Kang, J. Han, K. Lee, J. Choi, J. Park, H. Lee, H. Kim, J. Kim, S. Kang, Y. Oh, and S. Sheen

Low expression of bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4597. [Abstract]  

V. Gruenwald, L. Wilkens, M. Gebel, T. F. Greten, S. Kubicka, A. Ganser, M. P. Manns, and N. P. Malek

A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
J Clin Oncol (Meeting Abstracts) 2007 25: 4598. [Abstract]  

N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, D. S. Hong, L. H. Camacho, C. Ng, and R. Kurzrock

Curcumin and pancreatic cancer: Phase II clinical trial experience
J Clin Oncol (Meeting Abstracts) 2007 25: 4599. [Abstract]  

W. Ichikawa, T. Takahashi, and Y. Sasaki

Pharmacogenetic profiling and clinical outcome of patients (pts) with advanced gastric cancer (AGC) treated with S-1 monotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4600. [Abstract]  

F. D. Huitzil, M. Capanu, G. Jacobs, W. Smith, E. O’Reilly, M. Shah, G. K. Schwartz, L. B. Saltz, D. P. Kelsen, and G. K. Abou-Alfa

Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4601. [Abstract]  

S. Im, S. Kim, J. Kim, H. Lee, M. Kim, S. Kim, W. Kang, H. Yang, I. Song, and Y. Bang

A phase II trial of perioperative chemotherapy with folinic acid, 5-fluorouracil, and oxaliplatin in potentially resectable gastric cancer with regional lymph node metastasis
J Clin Oncol (Meeting Abstracts) 2007 25: 4602. [Abstract]  

Y. Bang, Y. Kang, W. Kang, N. Boku, H. Chung, S. Lanzalone, M. J. Lechuga, L. Sherman, R. Chao, and A. Sobrero

Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study
J Clin Oncol (Meeting Abstracts) 2007 25: 4603. [Abstract]  

F. L. Rojas Llimpe, F. Di Fabio, C. Ceccarelli, C. Pinto, S. Siena, S. Cascinu, C. Funaioli, V. Mutri, S. Giaquinta, and A. A. Martoni

Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study)
J Clin Oncol (Meeting Abstracts) 2007 25: 4604. [Abstract]  

P. Sunpaweravong, S. Sunpaweravong, D. Sangthawan, P. Puttawibul, and W. Mitarnun

Combination of gefitinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4605. [Abstract]  

S. Hashmi, G. Black, D. Bell, A. Steg, M. Johnson, R. B. Diasio, and M. W. Saif

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival
J Clin Oncol (Meeting Abstracts) 2007 25: 4606. [Abstract]  

H. Oettle, T. Seufferlein, R. Schmid, T. Luger, S. Ludwig, S. Schmaus, G. Wuerth, H. Heinrichs, and K. Schlingensiepen

Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- ß2 inhibitor AP 12009
J Clin Oncol (Meeting Abstracts) 2007 25: 4607. [Abstract]  

J. A. Wallace, G. Locker, S. Nattam, K. Kasza, K. Wade-Oliver, W. M. Stadler, E. E. Vokes, and H. L. Kindler

Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium
J Clin Oncol (Meeting Abstracts) 2007 25: 4608. [Abstract]  

K. Fujitani, M. Sasako, Y. Iwasaki, K. Yoshimura, T. Sano, A. Nashimoto, N. Fukushima, K. Arai, T. Kinoshita, O. Kobayashi, and H. Tanemura

A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210
J Clin Oncol (Meeting Abstracts) 2007 25: 4609. [Abstract]  

B. C. Pestalozzi, S. Heinrich, M. Schäfer, and C. Pierre-Alain

Neoadjuvant chemotherapy for resectable adenocarcinoma of the panctreatic head - a prospective phase II trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4610. [Abstract]  

C. Gomez-Martin, J. C. Camara, H. Cortes, C. Jara, C. Gravalos, B. Rubio, M. L. Amador, and M. Hidalgo

A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4611. [Abstract]  

J. A. Ajani, A. Phan, L. Ho, E. D. Tetzlaff, J. Baker, and Q. Wei

Phase I/II trial of docetaxel plus oxaliplatin and 5-fluorouracil (D-FOX) in patients with untreated, advanced gastric or gastroesophageal cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4612. [Abstract]  

H. Cortés-Funes, F. Rivera, I. Alés, A. Márquez, A. Velasco, R. Colomer, R. García-Carbonero, J. Sastre, J. Guerra, and C. Grávalos

Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification
J Clin Oncol (Meeting Abstracts) 2007 25: 4613. [Abstract]  

T. D. Yan, D. Black, P. H. Sugarbaker, Y. Yonemura, J. Zhu, and D. L. Morris

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4614. [Abstract]  

Z. K. Stadler and K. E. Stuart

Characteristics, treatment and outcome of patients with hepatocellular carcinoma (HCC) in the United States: An analysis of 328 patients from 1998–2005
J Clin Oncol (Meeting Abstracts) 2007 25: 4615. [Abstract]  

F. W. Nugent, C. Cunningham, M. A. Barve, W. Fisher, H. Patel, E. Meiri, Y. V. Oza, Z. Yang, E. C. Jurkowski, and M. J. Uprichard

Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4616. [Abstract]  

A. O. Kaseb, M. Bansal, I. Wollner, V. Shah, D. Moonka, G. Divine, and M. Abouljoud

A 10-year retrospective analysis of risk factors, patterns of cancer recurrence, and survival after liver transplant for cirrhosis and hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4617. [Abstract]  

L. Yan, Y. Hu, M. R. D’Andrea, M. A. Towers, Y. Wang, P. Kesavan, M. DeWitte, M. T. Nakada, and S. Ahrendt

Association between high tumor CCL2 expression and poor survival in patients with resectable pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4618. [Abstract]  

M. Harlan, E. Sheehy, J. Randazzo, D. Schrag, M. M. Kemeny, D. P. Kelsen, and M. A. Shah

Initial findings from the Memorial Sloan-Kettering Early Onset and Familial Gastric Cancer Registry (EOFGCR)
J Clin Oncol (Meeting Abstracts) 2007 25: 4619. [Abstract]  

G. Cadiot, F. Bonnetain, B. Landi, O. Bouché, E. Mitry, L. Bedenne, P. Ruszniewski, F. Ricard, F. Vitry, and J. L. Jouve

Simplified LV5FU2-irinotecan (FOLFIRI) in the first-line therapy of well-differentiated endocrine carcinomas of the duodeno- pancreatic area: Preliminary results of the FFCD 0302 phase II trial with GTE participation
J Clin Oncol (Meeting Abstracts) 2007 25: 4620. [Abstract]  

S. Iqbal, B. Goldman, H. J. Lenz, C. M. Fenoglio-Preiser, and C. D. Blanke

S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4621. [Abstract]  

A. Mancuso, S. Sacchetta, P. Saletti, C. Tronconi, L. Milesi, M. Garassino, O. Martelli, R. Labianca, F. Cavalli, and C. N. Sternberg

Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: results of an Italian/Swiss multicenter survey
J Clin Oncol (Meeting Abstracts) 2007 25: 4622. [Abstract]  

Y. Yamada, T. Arao, K. Nishio, F. Koizumi, D. Saito, T. Gotoda, T. Shimoda, H. Taniguchi, K. Shirao, N. Saijo, and M. Sasako

Identification of prognostic biomarkers for gastric cancer by gene expression analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 4623. [Abstract]  

M. Wiedmann, M. Haefner, M. Niederhagen, K. Schoppmeyer, C. Wittekind, C. Moebius, J. Mossner, and K. Caca

Treatment of pancreatic cancer with two novel histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589
J Clin Oncol (Meeting Abstracts) 2007 25: 4624. [Abstract]  

J. W. Clark, J. A. Meyerhardt, D. V. Sahani, S. Namasivayam, T. A. Abrams, K. Stuart, P. Bhargava, L. S. Blaszkowsky, S. R. Jain, and A. X. Zhu

Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 4625. [Abstract]  

S. OH, H. Kwon, H. Yoo, S. Lee, S. Kim, S. Kim, J. Jang, M. Kim, J. Jeong, K. Kim, and H. Kim

Preoperative level of VEGF and IL-6 are associated with lymph node invasion and stage in gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4626. [Abstract]  

D. J. Cohen, T. Ryan, E. Newman, S. Iqbal, M. Liu, M. Utate, S. Moore, M. Potmesil, H. Hochster, and F. M. Muggia

Intraperitoneal(IP) 5’-fluoro-2’deoxyuridine(FUDR): Safety and outcome when administered prior to adjuvant chemoradiotherapy(chemoRT) following R₀ resection for gastric adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4627. [Abstract]  

M. Reni, S. Cereda, P. Passoni, A. Rognone, E. Mazza, R. Nicoletti, P. G. Arcidiacono, A. Zerbi, G. Balzano, and V. Di Carlo

A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4628. [Abstract]  

T. Nishina, J. Matsubara, M. Toshikazu, Y. Yamada, T. Kajiwara, T. Shimoda, Y. Okayama, Y. Sugimoto, T. Oka, and K. Shirao

Clinical significance of dihydropyrimidine dehydrogenase (DPD), epidermal growth factor receptor (EGFR), and excision repair cross-complementing gene 1 (ERCC1) gene expression of tumor tissue in patients with advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4629. [Abstract]  

H. Takamori, K. Kanemitsu, A. Chikamoto, T. Ishiko, T. Beppu, M. Hirota, and H. Baba

A novel multimodality treatment for resectable pancreatic cancer (PC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4630. [Abstract]  

G. Y. Ku, D. Kelsen, B. Minsky, V. Rusch, M. Bains, and D. H. Ilson

Small cell carcinoma of the esophagus: Review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
J Clin Oncol (Meeting Abstracts) 2007 25: 4631. [Abstract]  

N. Mathieu, T. Aparicio, F. Roudot-Thoraval, N. Lemarchand, P. Bauer, C. Hennequin, E. Mitry, C. Romelaer, L. Abramowitz, and I. Sobhani

Comparison of squamous cell carcinoma of the canal anal (SCCA) prognosis in patients infected or not by human immunodeficiency virus (HIV)
J Clin Oncol (Meeting Abstracts) 2007 25: 4632. [Abstract]  

S. R. Park, M. S. Park, Y. L. Park, N. K. Kim, J. S. Lee, H. K. Kim, and H. S. Lim

CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel
J Clin Oncol (Meeting Abstracts) 2007 25: 4633. [Abstract]  

J. J. Lee, S. Y. Kim, H. C. Chung, K. H. Lee, H. S. Song, I. S. Woo, Y. S. Hong, W. K. Kang, J. H. Choi, and I. S. Choi

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy in patients with advanced or relapsed gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4634. [Abstract]  

K. Hiraiwa, H. Takeuchi, Y. Kitagawa, H. Hasegawa, Y. Saikawa, T. Ando, T. Irino, T. Yoshikawa, S. Ishii, and M. Kitajima

Circulating tumor cells detected in patients with gastrointestinal cancers associate with tumor stage and response to chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 4635. [Abstract]  

M. Nasu, H. Orita, M. Gibson, M. Brock, J. Herman, E. Gabrielson, M. Tsurumaru, and A. Forastiere

Normal esophageal mucosae adjacent to esophageal adenocarcinomas in both Japanese and U.S. patients have a field defect of methylation changes
J Clin Oncol (Meeting Abstracts) 2007 25: 4636. [Abstract]  

A. X. Zhu, D. V. Sahani, E. di Tomaso, D. Duda, V. Sindhwani, S. S. Yoon, L. S. Blaszkowsky, J. W. Clark, D. P. Ryan, and R. K. Jain

A phase II study of sunitinib in patients with advanced hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4637. [Abstract]  

S. Shin, H. Jeung, J. Ahn, H. Choi, B. Cho, S. Rha, N. Yoo, J. Roh, H. Chung, and H. Chung

Mobilized circulating endothelial progenitor cells after the first cycle of chemotherapy with prophylactic G-CSF can be used as a predictive biomarker and patient selection marker for anti-angiogenesis combination treatment
J Clin Oncol (Meeting Abstracts) 2007 25: 4638. [Abstract]  

A. B. El-Khoueiry, C. Rankin, H. J. Lenz, P. Philip, S. E. Rivkin, and C. D. Blanke

SWOG 0514: A phase II study of sorafenib (BAY 43–9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas
J Clin Oncol (Meeting Abstracts) 2007 25: 4639. [Abstract]  

S. Sym, H. Chang, M. Ryu, J. Lee, T. Kim, J. Yook, S. Oh, B. Kim, and Y. Kang

A phase II study of neoadjuvant chemotherapy with docetaxel, capecitabine and cisplatin (DXP) in patients with advanced unresectable or intra-abdominal metastatic gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4640. [Abstract]  

M. Hassan, C. Dagohoy, C. Leary, D. Li, and J. C. Yao

Risk factors for low-grade neuroendocrine carcinoma (LGNET): Hospital-based case-control study in US
J Clin Oncol (Meeting Abstracts) 2007 25: 4641. [Abstract]  

H. Toh, Y. P. Phoon, R. Quek, A. H. Banham, and S. Y. Tan

Increased foxp3+ regulatory T cells predicts for superior relapse-free and overall survival in early stage hepatocelullar carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4642. [Abstract]  

T. Okusaka, T. Sato, S. Hinotsu, Y. Shioyama, H. Kasugai, K. Tanaka, M. Kudo, T. Saisho, Y. Osaki, M. Sata, and S. Fujiyama

Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: Results of a multicenter randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4643. [Abstract]  

D. Fu, J. Chong, C. Foss, J. Fox, S. Wang, G. Green, J. Chen, M. V. Lemas, M. Pomper, and R. Ambinder

Imaging and therapy for Epstein-Barr virus-associated gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4644. [Abstract]  

K. Kang, B. Choi, H. Jang, S. Bae, M. Ryu, Y. Kang, J. Jang, G. Choi, and I. Choi

Cyberknife stereotactic radiosurgery in patients with primary hepatocellular carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 4645. [Abstract]  

D. Morales-Espinosa, A. Martínez-Velasco, T. Cerón-Lizárraga, V. Rosas-Camargo, J. L. Rodríguez-Díaz, D. Flores- Estrada, A. Gamboa-Domínguez, and O. Arrieta

Clinical and pathologic factors associated with development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: A long-term follow-up study
J Clin Oncol (Meeting Abstracts) 2007 25: 4646. [Abstract]  

H. Chang, M. Azuma, B. Goldman, F. Nagashima, S. Iqbal, K. Danenberg, J. Benedetti, W. Zhang, C. Blanke, and H. Lenz

Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial
J Clin Oncol (Meeting Abstracts) 2007 25: 4647. [Abstract]  

A. Duffy, M. Capanu, G. K. Abou-Alfa, D. Huitzel, P. Williams, W. Jarnagin, Y. Fong, D. P. Kelsen, and E. M. O’Reilly

Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
J Clin Oncol (Meeting Abstracts) 2007 25: 4648. [Abstract]  

B. Keam, H. Kim, S. Im, H. Ham, S. Han, E. Cho, J. Lee, D. Oh, T. Kim, and Y. Bang

Comprehensive analysis of ERCC, XPD, and XRCC polymorphisms: Association with clinical outcomes in patients with advanced gastric cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 4649. [Abstract]  

Plenary:

B. L. Powell

Effect of consolidation with arsenic trioxide (As₂O₃) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710
J Clin Oncol (Meeting Abstracts) 2007 25: 2. [Abstract]  

B. Escudier, P. Koralewski, A. Pluzanska, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, N. Moore on behalf of the AVOREN investigators

A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-2a vs placebo/interferon- 2a as first-line therapy in metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2007 25: 3. [Abstract]  

B. Slotman, C. Faivre-Finn, G. Kramer, E. Rankin, M. Snee, M. Hatton, G. de Schaetzen, L. Collette, S. Senan on behalf of the EORTC Radiation Oncology and LungCancer Groups

A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993)
J Clin Oncol (Meeting Abstracts) 2007 25: 4. [Abstract]  

Breast Cancer:

B. Nordlinger, H. Sorbye, L. Collette, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, W. Bechstein, E. Walpole, and T. Gruenberger

Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases
J Clin Oncol (Meeting Abstracts) 2007 25: LBA5. [Abstract]  

P. Rastogi, J. Jeong, C. E. Geyer, J. P. Costantino, E. H. Romond, M. S. Ewer, D. L. Keefe, T. Levine, S. M. Swain, and N. Wolmark

Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)paclitaxel (T) vs. ACT with trastuzumab (H)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA513. [Abstract]  

J. A. Dewar, J. S. Haviland, R. K. Agrawal, J. M. Bliss, P. Hopwood, B. Magee, J. R. Owen, M. A. Sydenham, K. Venables, J. R. Yarnold on behalf of the START Trials centers

Hypofractionation for early breast cancer: First results of the UK standardization of breast radiotherapy (START) trials
J Clin Oncol (Meeting Abstracts) 2007 25: LBA518. [Abstract]  

M. W. Verrill, J. Lee, D. A. Cameron, R. Agrawal, R. E. Coleman, K. McAdam, A. Wardley, A. Bowman, L. Ferrigan, and A. Yellowlees

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1005. [Abstract]  

M. Pegram, J. Forbes, T. Pienkowski, V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, J. Crown, H. Taupin, D. Slamon on behalf of the BCIRG007 investigators

BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
J Clin Oncol (Meeting Abstracts) 2007 25: LBA1008. [Abstract]  

Breast CancerLocal-Regional and Adjuvant:

J. Mortimer, S. Flatt, B. Parker, E. Gold, J. P. Pierce Women’s Healthy Eating and Living (WHEL) Investigators

Tamoxifen, hot flashes, and breast cancer recurrence: Support for pharmacogenetics
J Clin Oncol (Meeting Abstracts) 2007 25: 500. [Abstract]  

V. Stearns, D. F. Hayes, L. Li, J. Robarge, T. Skaar, A. Nguyen, A. Schott, A. Storniolo, D. A. Flockhart, Y. Jin Consortium on Breast Cancer pharmacogenomics (COBRA)

Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms
J Clin Oncol (Meeting Abstracts) 2007 25: 501. [Abstract]  

R. S. Punglia, E. P. Winer, J. C. Weeks, and H. J. Burstein

Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis
J Clin Oncol (Meeting Abstracts) 2007 25: 502. [Abstract]  

D. Serrano, D. Macis, S. Gandini, H. Johansson, A. Guerrieri-Gonzaga, G. Mellgren, E. A. Lien, F. Mariett, M. Sandri, A. Decensi, and B. Bonanni

Correlation of low dose tamoxifen and its metabolites plasma level with Cyp 2D6, and SULT polymorphism; a pharmacogenetics study within a chemoprevention trial
J Clin Oncol (Meeting Abstracts) 2007 25: 503. [Abstract]  

M. Rizzo, N. Reisman, S. G. Gabram, H. L. Bumpers, J. Okoli, O. W. Brawley, and M. Lund

Differences in treatment in stage III breast cancer in African American women
J Clin Oncol (Meeting Abstracts) 2007 25: 504. [Abstract]  

L. Favier, A. Berriolo-Riedinger, B. Coudert, C. Touzery, J. Riedinger, M. Toubeau, L. Arnould, F. Brunotte, and P. Fumoleau

Predicative value of [18F]-FDG PET scan for pathological complete response to neoadjuvant chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 505. [Abstract]  

L. Dunnwald, J. Gralow, G. Ellis, R. Livingston, H. Linden, J. Specht, R. Doot, T. Lawton, W. Barlow, and D. Mankoff

Tumor metabolism, blood flow changes, and prognosis by positron emission tomography: A prospective cohort of locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 506. [Abstract]  

V. Russu, B. Lex, M. Popovich, K. Pfaffenberger, H. Volkholz, and A. Tulusan

MRI of the breast before and after primary systemic therapy correlates with histopathological tumor size in patients with locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2007 25: 507. [Abstract]  

M. P. Patel, S. Saha, S. Ali, D. Iddings, D. Wiese, H. Sankaran, M. Arora, T. Singh, T. Branigin, and K. Barber

Comparative analysis of bone marrow (BM) micrometastasis (M) with sentinel lymph node (SLN) status in early breast cancer (BRCa)
J Clin Oncol (Meeting Abstracts) 2007 25: 508. [Abstract]  

S. M. Swain, S. M. Steinberg, Z. Modrusan, V. Smith, F. de Sauvage, and S. X. Yang

Molecular pathways and gene ontology categories in association with response to combination chemotherapy plus bevacizumab in inflammatory and locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 509. [Abstract]  

D. G. Generali, A. Berruti, S. B. Fox, M. Brizzi, S. Bonardi, M. Milani, A. Bersiga, R. Dionisio, L. Dogliotti, A. Bottini, and A. L. Harris

Down-regulation of HIF-1 expression by letrozole in ER+ve breast cancer patients
J Clin Oncol (Meeting Abstracts) 2007 25: 510. [Abstract]  

S. Paik, C. Kim, J. Jeong, C. E. Geyer, E. H. Romond, O. Mejia-Mejia, E. P. Mamounas, D. Wickerham, J. P. Costantino, and N. Wolmark

Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31
J Clin Oncol (Meeting Abstracts) 2007 25: 511. [Abstract]  

E. A. Perez, E. H. Romond, V. J. Suman, J. Jeong, N. E. Davidson, C. E. Geyer, S. Martino, E. P. Mamounas, P. A. Kauffman, N. Wolmark NCCTG/NSABP

Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 512. [Abstract]  

A. M. Storniolo, M. Koehler, A. Preston, E. Rappold, J. Byrne, and M. S. Ewer

Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA)
J Clin Oncol (Meeting Abstracts) 2007 25: 514. [Abstract]  

J. A. Sparano, M. Wang, S. Martino, V. Jones, E. Perez, T. Saphner, A. C. Wolff, G. W. Sledge, Jr, W. C. Wood, and N. E. Davidson

Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199
J Clin Oncol (Meeting Abstracts) 2007 25: 516. [Abstract]  

D. M. Loesch, F. Greco, J. O’Shaughnessy, J. D. Hainsworth, S. J. Vukelja, J. Sandbach, K. A. Boehm, D. Ilegbodu, L. Asmar, and N. J. Robert

A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
J Clin Oncol (Meeting Abstracts) 2007 25: 517. [Abstract]  

M. N. Ibrahim, Z. Abdullah, L. Healy, C. Murphy, I. Y. Yousif, and M. J. Martin

Comparison of survival rates in carcinoma in situ of the breast treated with total mastectomy to breast-conserving surgery and radiotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 519. [Abstract]  

I. Wapnir, J. Dignam, T. B. Julian, S. Land, E. P. Mamounas, S. Anderson, V. Fourchotte, J. Costantino, and N. Wolmark

Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24
J Clin Oncol (Meeting Abstracts) 2007 25: 520. [Abstract]  

A. S. Coates, H. Mouridsen, Z. Sun, M. Rabaglio, M. Castiglione-Gertsch, B. Thürlimann, L. Mauriac, K. N. Price, M. Colleoni, and I. Smith

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98
J Clin Oncol (Meeting Abstracts) 2007 25: 521. [Abstract]  

C. K. Anders, S. D. Hsu, C. R. Acharya, Y. Zhang, Y. Wang, J. A. Foekens, P. K. Marcom, J. R. Marks, J. Nevins, A. Potti, and K. L. Blackwell

Molecular signatures characterize early stage breast cancer arising in young women and have prognostic and therapeutic implications independent of ER status
J Clin Oncol (Meeting Abstracts) 2007 25: 522. [Abstract]  

M. Filipits, M. Rudas, M. Lehnert, E. Kubista, O. Dietze, R. Greil, S. Lax, H. Samonigg, R. Jakesz, M. Gnant G. Austrian Breast and Colorectal Cancer Study Group

Cyclin D1 expression in breast cancer patients and tamoxifen therapy
J Clin Oncol (Meeting Abstracts) 2007 25: 523. [Abstract]  

M. F. Press, G. Sauter, M. Buyse, L. Bernstein, W. Eiermann, T. Pienkowski, V. Bee, H. Taupin, S. Seelig, and D. J. Slamon

Alteration of topoisomerase II-alpha gene in human breast cancer and its association with responsiveness to anthracycline- based chemotherapy
J Clin Oncol (Meeting Abstracts) 2007 25: 524. [Abstract]  

C. M. Dumontet, J. C. Reed, M. Krajewska, I. Treilleux, J. R. Mackey, M. Martin, C. Vogel, M. Rupin, E. Brunel, and J. Hugh

BCIRG 001 molecular analysis: Identification of prognostic factors in patients (pts) receiving adjuvant therapy for node- positive (N+) breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2007 25: 525. [Abstract]  

L. J. Goldstein, R. Gray, B. H. Childs, D. Watson, S. G. Rowley, S. Shak, S. Badve, N. E. Davidson, G. W. Sledge, Jr., and J. A. Sparano

Abstract Submission
J Clin Oncol (Meeting Abstracts) 2007 25: 526. [Abstract]  

A. Makris, C. Creighton, K. C. Osborne, S. Hilsenbeck, M. K. Harrison, P. J. Ostler, C. Spears, P. Brown, R. Elledge, and J. C. Chang

Predictive gene expression patterns of response to adriamycin and cyclophosphamide (AC) in human breast cancers
J Clin Oncol (Meeting Abstracts) 2007 25: 527. [Abstract]  

J. C. Chang, X. Li, H. Wong, C. Creighton, S. G. Hilsenbeck, C. K. Osborne, J. M. Rosen, and M. T. Lewis

Therapeutic resistance and tumor-initiation: Molecular pathways involved in breast cancer stem cell self-renewal
J Clin Oncol (Meeting Abstracts) 2007 25: 528. [Abstract]